Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period.

MLA

Seino, Yutaka, et al. “Efficacy and Safety of Luseogliflozin Added to Insulin Therapy in Japanese Patients with Type 2 Diabetes: A Multicenter, 52-Week, Clinical Study with a 16-Week, Double-Blind Period and a 36-Week, Open-Label Period.” Current Medical Research and Opinion, vol. 34, no. 6, June 2018, pp. 981–94. EBSCOhost, https://doi.org/10.1080/03007995.2018.1441816.

APA

Seino, Y., Sasaki, T., Fukatsu, A., Imazeki, H., Ochiai, H., & Sakai, S. (2018). Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period. Current Medical Research and Opinion, 34(6), 981–994. https://doi.org/10.1080/03007995.2018.1441816

Chicago

Seino, Yutaka, Takashi Sasaki, Atsushi Fukatsu, Hisae Imazeki, Hidekazu Ochiai, and Soichi Sakai. 2018. “Efficacy and Safety of Luseogliflozin Added to Insulin Therapy in Japanese Patients with Type 2 Diabetes: A Multicenter, 52-Week, Clinical Study with a 16-Week, Double-Blind Period and a 36-Week, Open-Label Period.” Current Medical Research and Opinion 34 (6): 981–94. doi:10.1080/03007995.2018.1441816.